Solventum (NYSE:SOLV) Issues FY 2025 Earnings Guidance

Solventum (NYSE:SOLV) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 5.450-5.650 for the period, compared to the consensus EPS estimate of 5.490. The company issued revenue guidance of -.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on SOLV shares. Mizuho began coverage on Solventum in a research report on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 price objective for the company. Bank of America raised their price target on shares of Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research report on Wednesday. Piper Sandler raised their target price on Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research report on Friday, November 8th. Finally, Morgan Stanley boosted their price target on shares of Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and one has given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $71.86.

Solventum Stock Down 0.7 %

NYSE:SOLV opened at $83.46 on Friday. The company’s 50-day moving average price is $72.25 and its two-hundred day moving average price is $69.73. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. Solventum has a 12 month low of $47.16 and a 12 month high of $96.05.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.